Selectin inhibitors: a patent review

Bibliography

• Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008;111(11):5271-81
   Google Scholar
• Kaila N, Somers WS, Thomas BE, Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin. J Med Chem 2005;48(13):4346-57
   Google Scholar
• Somers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to sLex and PSGL-1. Cell 2000;103(3):467-79
   Google Scholar
• Leppänen A, Yago T, Otto VI, Model glycosulfopeptides from P-selectin glycoprotein ligand-1 require tyrosine sulfation and a core 2-branched O-glycan to bind to l-selectin. J Biol Chem 2003;278(29):26391-400
   Google Scholar
• Frennette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost 1997;78(1):60-4
   Google Scholar
• Ludwig RJ, Schön MP, Boehncke W-H. P-selectin. Expert Opin Ther Targets 2007;11(8):1103-17
   Google Scholar
• Rossi B, Constantin G. Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 2008;7(2):85-93
   Google Scholar
• Boehncke W-H, Schön MP. Interfering with leukocyte rolling – a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 2003;24(2):49-52
   Google Scholar
• Kaila N, Thomas BE. Selectin inhibitors. Expert Opin Ther Patents 2003;13(3):305-17
   Google Scholar
• Regents of the University of California. Heparin compositions and selectin inhibition. WO2007014049; 2007
   Google Scholar
• Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007;120(Suppl 2):S107-S11
   Google Scholar
• Hostettler N, Naggi A, Torri G, P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007;21(13):3562-72
   Google Scholar
• Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Cur Drug Discov Technol 2009;6:281-9
   PubMedGoogle Scholar
• Min W, Yanguang G, Meihong T, Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. Cancer Lett 2005;229(1):123-6
   Google Scholar
• Adis R&D Insight Database. PGX 100. Wolters Kluwer Health; 2009
   Google Scholar
• ParinGenix. A study designed to evaluate ODSH in subjects with exacerbations of COPD. National Institutes of Health; 2009
   Google Scholar
• GlycoMimetics, Inc. Glycomimetic antagonists for both E-and P-selectins. WO2005054264; 2005
   Google Scholar
• GlycoMimetics, Inc. Specific antagonist for both E-and P-selectins. WO2005051920; 2005
   Google Scholar
• GlychoTech, Inc. Compounds and methods for inhibiting selectin-mediated function. WO2003097658; 2003
   Google Scholar
• GlycoMimetics, Inc. Heterobifunctional pan-selectin inhibitors. WO2007028050; 2007
   Google Scholar
• GlycoMimetics, Inc. Glycomimetic replacements for hexoses and N-acetyl hexosamines. US20080161546; 2008
   Google Scholar
• GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines. US20080200406; 2008
   Google Scholar
• ClinicalTrials.gov. Study of intravenous GMI-1070 in adults with sickle cell disease. NIH; 2009
   Google Scholar
• Chang J, Patton J, Sarkar A, A novel selectin antagonist, GMI-1070, prevents vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and activation. 49th Annual Meeting; American Society of Hematology. Blood 2007;110(11):2245
   Google Scholar
• Texas Biotechnology Corp. Di-and trivalent small molecule selectin inhibitors. WO1997001335; 1999
   Google Scholar
• Beeh K, Beier J, Meyer M, Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2006;19(4):233-41
   Google Scholar
• Friedrich M, Bock D, Philipp S, Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 2006;297(8):345-51
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of bimosiamose cream to treat psoriasis. NIH; 2009
   Google Scholar
• ClinicalTrials.gov. Study to evaluate the effect of bimosiamose on ozone induced sputum neutrophilia. NIH; 2009
   Google Scholar
• Revotar Biopharmaceuticals AG. Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyl-oxy)-phenyl] hexane. WO2008028966; 2008
   Google Scholar
• Revotar Biopharmaceuticals AG. Use of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions. WO2008028950; 2008
   Google Scholar
• Revotar Biopharmaceuticals AG. Pharmaceutical composition for the treatment of IL-8 mediated diseases. WO2008098985; 2008
   Google Scholar
• Malhotra R, Ward M, Bright H, Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 2003;5(2):123-33
   Google Scholar
• Insight. ARD. Bimosiamose; 2009
   Google Scholar
• Taisho Pharma Co., Ltd. Persulfated oligosaccharide acting on selectins and chemokine. WO2004011662; 2006
   Google Scholar
• Revotar Biopharmaceuticals AG. Novel phloroglucinol derivatives having selectin ligand activity. WO2007039112; 2007
   Google Scholar
• Revotar Biopharmaceuticals AG. Non-glycosylated/non-glycosidic/ non-peptidic small molecule PSGL-1 mimetics for the treatment of inflammatory disorders. WO2005090284; 2005
   Google Scholar
• Revotar Biopharmaceuticals AG. Novel multi-cyclic compounds. WO2007039111; 2007
   Google Scholar
• Revotar Biopharmaceuticals AG. Novel aromatic compounds and their use in medical applications. WO2007039113; 2007
   Google Scholar
• Revotar Biopharmaceuticals AG. Novel nitrocatechol derivatives having selectin ligand activity. WO2007039114; 2007
   Google Scholar
• Wyeth Corp. Methods and compositions for selectin inhibition. WO2005047258; 2005
   Google Scholar
• Wyeth Corp. Methods and compositions for selectin inhibition. WO2005047257; 2005
   Google Scholar
• Bedard PW, Clerin V, Sushkova N, Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther 2008;324(2):497-506
   Google Scholar
• Kaila N, Janz K, Huang A, 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. J Med Chem 2006;50(1):40-64
   Google Scholar
• Clerin V, Resmini C, Wong T, WAY-197697, a P-selectin antagonist, reduces atherosclerosis in apolipoprotein E deficient mice. Intern Soc Thromb Haemost Meeting. J Thromb Haemost 2005;3(Suppl 1): abstract P2355
   Google Scholar
• Myers DD Jr, Henke PK, Bedard PW, Treatment with an oral small molecule inhibitor of P-selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 2006;44(3):625-32
   Google Scholar
• Myers DD Jr, Wrobleski S, Longo C, Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. J Thromb Haemost 2007;97(3):400-7
   Google Scholar
• Chelliah R, Lucking AJ, Tattersall L, P-selectin antagonism reduces thrombus formation in humans. J Thromb Haemost 2009;11:1915-9
   Google Scholar
• Wyeth Corp. Methods and compositions for selectin inhibition. WO2008121805; 2008
   Google Scholar
• Wyeth Corp. Methods and compositions for selectin inhibition and quinoline derivatives and pharmaceutical compositions comprising them for selectin inhibition. WO2008121817; 2008
   Google Scholar
• Meier T, Myers DD Jr, Wrobleski S, Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. J Thromb Haemost 2008;99(2):343-51
   Google Scholar
• Rimonyx Pharmaceuticals Ltd. Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof. WO2004069149; 2008
   Google Scholar
• University of Mainz Johannes Gutenberg. Non-glycosidic and non-peptidic selectin inhibitors, and the use thereof. WO2006010598; 2006
   Google Scholar
• Astellas Pharma, Inc (Yamanouchi Pharma). P-selectin targeting ligand and compositions there of WO2004105783; 2007
   Google Scholar
• Astellas Pharma, Inc (Yamanouchi Pharma Co LTD). Polyhydroxy phenols and their use in binding P-selectin. WO2004105740; 2007
   Google Scholar
• Astellas Pharma Europ BV. Compounds binding to P-selectin. WO2004018502; 2009
   Google Scholar
• Astellas Pharma Europ BV (Yamanouchi Europ BV). Glucose-based compounds with affinity to P-selectin. WO2004033473; 2007
   Google Scholar
• Freie Uni Berlin; Charité Universitaetsmedizin. Dendritic polyglycerol sulfates and sulfonates and their use for inflammatory diseases. WO2008015015; 2008
   Google Scholar
• Genetics Institute LLC; Temple University. Modulation of leukocyte-endothelial interactions following ischemia. US20030083258; 2003
   Google Scholar
• Gaber AO, Moore LW, Mulgaonkar S, YSPSL (rPSGL-Ig) for the prevention of delayed graft function (DGF): Results of double-blind, placebo-controlled, multi-center phase I/II safety and efficacy study: 832. Transplantation 2008;86(2):290
   Google Scholar
• ClinicalTrials.gov. YSPSL for prevention of ischemic reperfusion injury in patients undergoing cadaveric orthotopic liver transplantation. NIH; 2009
   Google Scholar
• Amersi F, Farmer DG, Shaw GD, P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002;2(7):600-8
   Google Scholar
• Chen Y, Ruetzler C, Pandipati S, Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci USA 2003;100(25):15107-12
   Google Scholar
• Reuters. Novavax inc (nvax.O) company profile. 2009. Available from: http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=NVAX.O. [Cited 28 October 2009]
   Google Scholar
• PJB Pharmaprojects PRDPI. CY-1787. Informa; 2009
   Google Scholar
• Aeres Biomedical Ltd. Antibodies to P-selectin and their uses. EP642356; 2003
   Google Scholar
• Ligocyte Pharmaceuticals, Inc.; Univ Montana. Methods for the treatment and prevention of infection using anti-selectin agents. WO2006083322; 2006
   Google Scholar
• Jutila M, Watts G, Walcheck B, Kansas G. Characterization of a functionally important and evolutionarily well-conserved epitope mapped to the short consensus repeats of E-selectin and L-selectin. J Exp Med 1992;175(6):1565-73
   Google Scholar
• Hoffmann La Roche, Inc. Anti-P-selectin antibodies. US20050226876; 2005
   Google Scholar
• Selexys Pharmaceuticals Corp. Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases. WO2008069999; 2008
   Google Scholar
• Jenison R, Jennings S, Walker D, Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 1998;8(4):265-79
   Google Scholar
• IMS R&D Focus. Aptamers targeted to P-selectin and to L-selectin for the treatment of inflammatory disorders,. IMS Health Global Services; 2003
   Google Scholar
• IMS R&D Focus. Aptamer P-selectin inhibitor for the potential treatment of sickle cell disease. IMS Health Global Services; 2008
   Google Scholar
• Archemix Corp. Nucleic acid ligand to B. anthracis protective antigen. WO2004085665; 2004
   Google Scholar
• Eisai Co., Ltd. Deazapurines and uses thereof. US7314936; 2008
   Google Scholar
• Eisai Co., Ltd. Novel deazapurines and uses thereof. WO2004063336; 2004
   Google Scholar
• Eisai Co., Ltd. Deazapurines and uses thereof. WO2003057696; 2003
   Google Scholar
• Novogen Research PTY LTD. Treatment of restenosis. US20050119301; 2005
   Google Scholar
• Saif MW, Tytler E, Lansigan F, Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Exp Opin Investig Drugs 2009;18(4):469-79
   Google Scholar
• Eberhard Karls University. Sirna molecules for the treatment of blood vessels. WO2006077112; 2008
   Google Scholar
• Walker T, Wendel HP, Tetzloff L, Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. J Cell Mol Med 2007;11(1):139-47
   Google Scholar
• Antisense Pharma GmbH. Pharmaceutical composition. WO2005084712; 2005
   Google Scholar
• Schlingensiepen K, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: The TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008;177:137-50
   PubMedGoogle Scholar
• Gardiner EE, De Luca M, McNally T, Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood 2001;98(5):1440-7
   Google Scholar
• Ward CM, Vinogradov DV, Andrews RK, Berndt MC. Characterization of mocarhagin, a cobra venom metalloproteinase from Naja mocambique mocambique, and related proteins from other Elapidae venoms. Toxicon 1996;34(10):1203-6
   Google Scholar
• Genetics Institute. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof. US6413760; 2002
   Google Scholar
• Barbas A, White R. The development and testing of aptamers for cancer. Cur Opin Investig Drugs 2009;10(6):572-8
   Google Scholar